Current Drug Shortages (.xls)
The Current Drug Shortages list provides details about drugs covered by PharmaCare that are in short supply at B.C. community pharmacies. It includes coverage options and alternative drugs that PharmaCare is covering during the shortage. The list does not include drugs used in hospitals. The Resolved Drug Shortages list provides details about drug shortages that have ended, including when the shortage resolved and how the shortage was mitigated.
Active advisories
Lomustine capsules
- Shortage: Ceenu (lomustine) 10 mg (DIN 360430) and 40 mg (DIN 360422) capsules
- Mitigation: US-authorized lomustine 10 mg capsules (use PIN 9858359) and UK-authorized lomustine 40 mg capsules (use PIN 9858382)
- Effective date: January 5, 2026
- Ordering: Available through McKesson
- Expected resolution: Unknown
- Notes:
- Lomustine is not a PharmaCare benefit
- Foreign-authorized lomustine is more costly than Canadian-authorized lomustine
- Resources:
Progesterone USP 50mg/mL for injection
- Shortage: Progesterone Injection 50mg/mL, DIN 02531828
- Mitigation: Hikma’s US-authorized Progesterone USP 50mg/mL for injection. Use PIN 66128596. US-authorized product has same coverage as Canadian product
- Effective date: December 19, 2025
- Expected resolution: January, 2026
- Resources:
Spironolactone tablets
- Shortage: Spironolactone 25 mg and 100 mg tablets (multiple brands)
- Mitigation: Refer to Spironolactone shortage (PDF, 285KB) for guidance on using alternative therapies. Consider alternative anti-hypertensives for management of simple hypertension
- Reason: Teva and Mint are reporting shortages because of manufacturing disruptions. Pfizer is reporting a shortage because of increased demand
- Expected resolution: Continued resupplies are expected in fall and supply should stabilize in December 2025
- Resources:
Ipratropium nebules
- Shortage: Ipratropium nebules, multiple DINs
- Mitigation: Consider other therapeutic alternatives
- Expected resolution: March 2026
- Resources:
Disopyramide capsules
- Shortage: Disopyramide capsules (brand name Rythmodan), DIN: 02224801
- Mitigation: US-labelled disopyramide 100mg capsules from Dr. Reddy’s Laboratories using PIN 09858365
- Effective date: July 16, 2025
- Ordering: Available through McKesson
- Expected resolution: Unknown
- Notes:
Olanzapine for injection
- Shortage: Olanzapine for injection, DIN 02416522
- Mitigation: SteriMax’s US-authorized olanzapine for injection. Use PIN 66128561. Olanzapine for injection is not a PharmaCare benefit
- Effective date: July 10, 2025
- Expected resolution: November, 2025
- Note: Consult the SteriMax advisory (PDF, 389 KB) for more information
Oxycodone/acetaminophen 5/325 mg
- Shortage: Oxycodone/acetaminophen 5/325 mg, multiple DINs
- Mitigation: Consider other opioids
- Expected resolution: Product is on allocation. Supply expected to stabilize in December 2025
- Note: Use the opioid conversion table in the Canadian Pharmacists Association resource below to make recommendations on equivalent doses
- Resources:
Praziquantel (Biltricide)
- Shortage: Praziquantel (Biltricide), DIN 2230897
- Mitigation: Use Biltricide 600 mg tab (Middle Africa), PIN 66128550 for processing prescriptions. Please note that praziquantel (Biltricide) is not a PharmaCare benefit
- Effective date: May 13, 2025
- Ordering: This medication can be ordered through usual wholesale distribution channels
- Expected resolution: Unknown
Peginterferon alfa-2a (Pegasys®) 180 mcg/0.5 mL pre-filled syringe
- Shortage: Peginterferon alfa-2a (Pegasys®) 180 mcg/0.5 mL pre-filled syringe, DIN 02248077
- Mitigation: Use US-labelled ropeginterferon alfa-2b (BESREMi®) 500 mcg/mL pre-filled syringe using PIN 09858357 or Irish-labelled Peginterferon alfa-2a (Pegasys) 180 mcg/0.5mL pre-filled syringe using PIN 09858366. Note that BESREMi and Pegasys are not eligible PharmaCare benefits. Direct eligible cancer patients who have been prescribed BESREMi or Pegasys to a BC Cancer centre or a Community Oncology Network site
- Effective date: March 26, 2025
- Ordering: Ordering Irish-labelled Pegasys is through various distributors. Ordering BESREMi in B.C. is direct from Forus Therapeutics Inc. To order, send an email to FORUS-CSR@innomar-strategies.com or call 1-866-542-7500
- Reason: Peginterferon is in shortage due to a demand increase and change in manufacturing site. Supply continues to be received but not in sufficient quantities. Restrictions on ordering are in place
- Expected resolution: Early 2026
- Resources:
- Note: Irish-labelled Peginterferon alfa-2a injection is packaged in cartons of 4 pre-filled syringes
Calcitriol injection USP 1 mcg/mL
- Shortage: Calcitriol injection USP 1 mcg/mL solution (DIN: 02399334)
- Mitigation: US supply imported. Use PIN 09858344 for processing
- Effective date: July 15, 2024
- Reason: Delay in shipping
- Expected resolution: Unknown
- Notes: US-supply calcitriol is a PharmaCare non-benefit, as with original Canadian product
Collagenase (Santyl®) ointment
- Update: US supply of collagenase (Santyl®) ointment has been imported into Canada and is available for order through McKesson Canada. Note that the US supply is now a regular PharmaCare benefit. Use PIN 066128469 to enter prescriptions into PharmaNet
- Effective date: April 25, 2024. Updated March 6, 2025
- Resources:
- Resolution: Intermittent US supply has been imported. Resolution is expected in 2026
Glucagon for injection
- Effective date: October 6, 2023
- Shortage: Glucagon for injection
- Mitigation: Use US-labelled glucagon from Amphastar Pharmaceuticals using PIN 09858279
- Notes:
- US labelled glucagon is limited coverage
- Special Authority details: Limited coverage drugs - glucagon
- Criteria: for the treatment of severe hypoglycemia in patients who the nasal spray dosage is not appropriate
- Amphastar's glucagon for injection is NOT considered equivalent to Eli Lilly's Canadian marketed glucagon (DIN 02243297). Please follow the US labelling when using Amphastar's glucagon, since there is no equivalent Canadian labelling available
- Baqsimi, a nasal formulation of glucagon, is available and is a regular PharmaCare benefit
Coverage for alternative drugs
PharmaCare may cover an alternative drug during a shortage. Coverage for the alternative drug is often the same as for the drug that is in short supply (e.g., the plan it is covered under and whether it needs Special Authority approval for coverage). To look up PharmaCare coverage of a specific drug, use the Formulary Search.
Sometimes the alternative is a foreign-labelled product. If this is the case, PharmaCare assigns the product a PIN, as it will not have a DIN.
For details on submitting a foreign-labelled product visit Foreign-authorized drug submissions.
PharmaCare may cover a compounded drug as the alternative drug on a last-resort basis.
When a shortage ends, the information is removed from the Current Drug Shortages list and is added to the Resolved Drug Shortages list, and any alternative product returns to its former benefit status.
PharmaCare often covers several versions of a drug. If one supplier’s version runs short, prescribers and pharmacists can consult the Low Cost Alternative program listings to learn whether another version is covered.
If PharmaCare is not covering an alternative drug
If there is no covered alternative drug, patients and their health care providers may need to discuss different treatment options.
Reasons for drug shortages
A drug shortage happens when a drug manufacturer or distributor cannot supply enough of a drug to meet demand. It can result from various supply and demand issues, including manufacturing delays, distribution issues (including importation) and product discontinuations.
Shortages happen fairly regularly. Most drug shortages are temporary, but permanent shortages may occur when a drug is discontinued.
Resolved Drug Shortages (.xls)